
CLAIMS

1. A compound having the systematic name 2-{5-fluoro-1-[(3-fluoropyridin-2-yl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-- yl}-5-methyl-5-(trifluoromethyl)-4-[(3,3,3-trifluoropropyl)amino]-5,7-dihy- dro-6H-pyrrolo[2,3-d]pyrimidin-6-one and the structural formula (I)


(I)



or a salt thereof.

2. An enantiomer of the compound of claim 1 having the systematic name (5R)-2-{5-fluoro-1-[(3-fluoropyridin-2-yl)methyl]-1H-pyrazolo[3,4-b]pyrid- in-3-yl}-5-methyl-5-(trifluoromethyl)-4-[(3,3,3-trifluoropropyl)amino]-5,7- -dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one and the structural formula (I-A)


(I-A)



or salt thereof.

3. An enantiomer of the compound of claim 1, having the systematic name (5S)-2-{5-fluoro-1-[(3-fluoropyridin-2-yl)methyl]-1H-pyrazolo[3,4-b]pyrid- in-3-yl}-5-methyl-5-(trifluoromethyl)-4-[(3,3,3-trifluoropropyl)amino]-5,7- -dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one and the structural formula (I-B)

(I-B)



or a salt thereof.

4. A pharmaceutical composition comprising a compound of claim 1 and an inert, non-toxic, pharmaceutically suitable auxiliary.

5. A pharmaceutical composition comprising a compound of claim 2 and an inert, non-toxic, pharmaceutically suitable auxiliary.

6. A pharmaceutical composition comprising a compound of claim 3 and an inert, non-toxic, pharmaceutically suitable auxiliary.

7. The pharmaceutical composition of claim 4, further comprising an active compound selected from the group consisting of an organic nitrate, an NO donor, a cGMP-PDE inhibitor, an agent having antithrombotic activity, an agent lowering blood pressure, and an agent altering lipid metabolism.


8. The pharmaceutical composition of claim 5, further comprising an active compound selected from the group consisting of an organic nitrate, an NO donor, a cGMP-PDE inhibitor, an agent having

antithrombotic activity, an agent lowering blood pressure, and an agent altering lipid metabolism.

9. The pharmaceutical composition of claim 6, further comprising an active compound selected from the group consisting of an organic nitrate, an NO donor, a cGMP-PDE inhibitor, an agent having antithrombotic activity, an agent lowering blood pressure, and an agent altering lipid metabolism.


10. A process for preparing a compound of claim 1, comprising converting a compound of the formula (II)

(II)




in an inert solvent using isopentyl nitrite and a halogen equivalent into a compound of the formula (III)

(III)




reacting the compound of formula (III) in an inert solvent, optionally in the presence of a suitable base, with a compound of the formula (IV)

(IV)



to give a compound of the formula (I)

(I)



and optionally converting the compound of the formula (I) with a (i) solvent and/or (ii) acid or base into solvate, salt and/or solvate of a salt thereof.

11. The process of claim 10, further comprising separating the compound of formula (I) into enantiomers thereof.